newsADC oncology therapy market to value over $36b by 20299 August 2023 | By Catherine Eckford (European Pharmaceutical Review)With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research shows Daiichi Sankyo, Seagen and Roche are currently three of the market's most important players.
newsAstellas to advance oncology CAR-T therapy7 August 2023 | By Catherine Eckford (European Pharmaceutical Review)An investment of $50 million by Astellas Pharma in Poseida Therapeutics’ Phase I allogeneic CAR-T product candidate for solid tumour indications is set to advance the cancer immunotherapy field.
newsWill ESR1-mutated breast cancer treatment gain approval?24 July 2023 | By Catherine Eckford (European Pharmaceutical Review)If approved by the European Commission (EC), ORSERDU® (elacestrant) would be the first treatment for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations.
newsUK ATMP clinical trials report 2022 published17 January 2023 | By Catherine Eckford (European Pharmaceutical Review)T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
newsOligonucleotide synthesis market to reach $16.7 billion by 20279 December 2022 | By Catherine Eckford (European Pharmaceutical Review)Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, states a new report.
newsSanofi to sell Japanese manufacturing plant17 October 2022 | By Catherine Eckford (European Pharmaceutical Review)Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
articleIssue #6 2016 – Digital version13 December 2016 | By European Pharmaceutical ReviewRead the free-to-view digital version of the latest issue of European Pharmaceutical Review...
newsESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)4 October 2016 | By Niamh Louise Marriott, Digital Content ProducerEuropean Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
newsBristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies28 September 2016 | By Niamh Louise Marriott, Digital Content ProducerBristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
newsInitiation of HTL1071 trial triggers $10m payment to Heptares6 July 2016 | By Victoria White, Digital Content ProducerThe first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
newsPositive results for Yeliva in Phase I advanced solid tumour study4 July 2016 | By Victoria White, Digital Content ProducerYeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities...
newsXilonix demonstrates significant clinical response in colorectal cancer study4 July 2016 | By Victoria White, Digital Content ProducerXBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)...
newsBMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer1 July 2016 | By Victoria White, Digital Content ProducerThe companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...
newsGlobal urological cancers market to double by 2022, says GBI Research30 June 2016 | By Victoria White, Digital Content ProducerThe urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
newsRegorafenib increases overall survival in hepatocellular carcinoma study29 June 2016 | By Victoria White, Digital Content ProducerResults from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
